Home › Therapeutic areas › Oncology › Endometrial Cancer
Endometrial Cancer (7 companies)
Companies with an active program in Endometrial Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 2 | Phase 2 | $69.0M | 9 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.39B | 9 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $186M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $503M | 10 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $67.4M | 7 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $2.10B | 11 |
No companies match.